Femasys Q3 2026: $30M private placement closed; U.S. sales flat, total sales fall 44.5% to $404,597
Femasys reported results for the quarter ended September 30, 2026, on November 13, 2026. Total sales fell 44.5% on the timing of international FemBloc orders, while U.S. sales rose slightly to $347,039. The company closed a $30 million private placement in mid-August to build out its U.S. commercial team for the FemaSeed fertility portfolio and to fund the FemBloc pivotal trial. It also reported FDA acceptance of a modular PMA approach for FemBloc and twelve actively enrolling FINALE trial sites. Net loss was $4.56 million and cash was about $23.9 million.
Company's press release (SEC filing): Femasys Inc ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
IM Cannabis reports C$13.9M nine-month net loss as revenue slides to C$9.0M
Mingteng International, an automotive mold maker, prices $2.00/share registered direct offering with pre-funded warrants
Organigram to acquire Aurora Cannabis for about C$561M, backed by BAT private placement and ATB credit facilities
Windward Bio prices Nasdaq IPO of 10.3 million shares at $17, targeting $225 million in gross proceeds
Lichen International prices $3.5M registered direct offering of units with warrants on Nasdaq
